TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35133064
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 0.1% (single dose)
Study: 35133064
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 0.1% (multiple doses, once daily for 7 days)
Study: 35133064
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 0.3% (single dose)
Study: 35133064
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 0.3% (multiple doses, once daily for 7 days)
Study: 35133064
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (single dose)
Study: 35133064
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (multiple doses, once daily for 7 days)
Study: 35115339
Drug: Budesonide/formoterol 200/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 200/6 µg
Study: 33724254
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg/day) plus pentoxifylline (400 mg three times daily)
Study: 33724254
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg/day) plus placebo
Study: 35834107
Drug: Diabetes-specific nutritional
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes-specific nutritional supplement (DSNS) plus standard of care (SOC)
Study: 33671220
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) 75 mg/kg body weight daily for 14 days
Study: 35293153
Drug: HFNCO (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFNCO (2 L/kg/min)
Study: 33864153
Drug: Fosfomycin-trometamol treatment
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin-trometamol treatment for ASB (77 patients)
Study: 35936366
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive therapy
Study: 34384540
Drug: Vi‐tetanus toxoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi‐tetanus toxoid conjugate vaccine (Vi‐TT)
Study: 34384540
Drug: SA 14‐14‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA 14‐14‐2 Japanese encephalitis (JE) vaccine
Study: 32799667
Drug: Electronic headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic headache diary (daily assessment of headache presence and severity)
Study: 32799667
Drug: Recall questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recall questionnaire (retrospective estimation of headache days on a monthly basis)
Study: 35440935
Drug: Coriander seed
Normalized name: coriander seed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coriander seed oil (CSO) 200 mg daily for 28 days
Study: 32692755
Drug: Heart rate-reducing
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate-reducing genetic variant at the HCN4 locus encoding ivabradine's drug target
Study: 33445213
Drug: Astaxanthin (AST)
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (AST) supplementation, 8 mg/d for 8 weeks
Study: 33536283
Drug: Isoniazid, pyrazinamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid, pyrazinamide, rifampicin, moxifloxacin (individual and in combination)
Study: 33536283
Drug: Isoniazid and
Normalized name: Isoniazid and rifampin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid and pyrazinamide (combination)
Study: 34605947
Drug: Adrecizumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrecizumab (2 or 4 mg/kg b.w.)
Study: 35986466
Drug: Spirulina 500
Normalized name: Spirulina 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina 500 mg twice daily along with topical triamcinolone acetonide 0.1% thrice daily for one week
Study: 35986466
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone acetonide 0.1% alone thrice daily for 8 weeks
Study: 34982738
Drug: IV vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vitamin C (1,000 mg bolus over 30 minutes followed by continuous infusion of 250 mg/hr for 96 hours)
Study: 33949215
Drug: 3-month intervention
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month intervention fostering self-efficacy and social support through weekly, family-centered sessions
Study: 34726703
Drug: GOS (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS (15 g) with FeFum (14 mg)
Study: 34726703
Drug: Control (FeFum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (FeFum 14 mg without GOS)
Study: 32565594
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg daily
Study: 33749992
Drug: Platelet gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet gel (PG)
Study: 36374528
Drug: Whole tablet
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablet oral administration (reference formulation)
Study: 33256796
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for 4 weeks
Study: 33256796
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment for 4 weeks
Study: 34090773
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber (oat bran) supplement (30 g/d, containing DF 8.9 g)
Study: 34090773
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber (oat bran) supplement
Study: 39678704
Drug: SQ HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ HDM SLIT-tablet
Study: 34101138
Drug: 0.07 mg
Normalized name: urea 0.07 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg LOR
Study: 33588087
Drug: 0.23 mg
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.23 mg LOR
Study: 35099281
Drug: 80% basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% basal insulin reduction applied 40 minutes before exercise onset (T-40)
Study: 35099281
Drug: 80% basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% basal insulin reduction applied 90 minutes before exercise onset (T-90)
Study: 34283040
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam sedation
Study: 34106628
Drug: Acupoint massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint massage combined with relaxation therapy
Study: 32310620
Drug: linaclotide 145
Normalized name: LINACLOTIDE 145MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: linaclotide 145 µg
Study: 32310620
Drug: linaclotide 290
Normalized name: LINACLOTIDE 290MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: linaclotide 290 µg
Study: 36906404
Drug: IIV4-HD (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-HD (high-dose quadrivalent inactivated influenza vaccine) administered intramuscularly (IM)
Study: 36906404
Drug: IIV4-SD (standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4-SD (standard-dose influenza vaccine) administered subcutaneously (SC)
Study: 36048453
Drug: modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified FOLFIRINOX (oxaliplatin, 85 mg/m2; irinotecan, 150-180 mg/m2; leucovorin, 400 mg/m2; fluorouracil, 2400 mg/m2, every 2 weeks)
Study: 36048453
Drug: gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000 mg/m2, days 1, 8, and 15, every 4 weeks)
Study: 37435938
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues
Study: 35121633
Drug: Immediate smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate smoking cessation support with pharmacotherapy
Study: 35570289
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual Optimized (TAU-O)
Study: 33752741
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg twice daily for 14 days
Study: 34644618
Drug: Modified electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified electroconvulsive therapy (MECT)
Study: 34644618
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drugs alone)
Study: 32302693
Drug: Febuxostat, 40
Normalized name: Febuxostat, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat, 40 mg daily during acute gout attack
Study: 32302693
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (febuxostat, 40 mg daily after attacks)
Study: 34169339
Drug: Intraoperative norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative norepinephrine > 0.11 µg/kg/min
Study: 33827126
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion rate of 0.1 μg/kg/min
Study: 33827126
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion rate of 0.2 μg/kg/min
Study: 33827126
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion rate of 0.4 μg/kg/min
Study: 33827126
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia with 2% lidocaine containing 12.5 μg/mL epinephrine
Study: 33827126
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (0.1, 0.2, 0.4 μg/kg/min)
Study: 32265500
Drug: Dasatinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100 mg)
Study: 32265500
Drug: Imatinib (≥400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (≥400 mg)
Study: 35101100
Drug: SBIRT (Screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT (Screening, Brief Intervention, and Referral to Treatment)
Study: 33692621
Drug: BreatheMate device
Approvals — FDA: no, EMA: no, PMDA: no
Description: BreatheMate device with electronic reminders for budesonide/formoterol 160/4.5 μg twice daily
Study: 33692621
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same medication without electronic reminders
Study: 34855657
Drug: Diterpene ginkgolides
Normalized name: terpene resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diterpene ginkgolides meglumine injection (DGMI) 25 mg/d for 14 days
Study: 36262727
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg nitroglycerine (Group N4)
Study: 36262727
Drug: 800 μg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 μg nitroglycerine (Group N8)
Study: 32522503
Drug: Bitter-flavoured, 7.5mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter-flavoured, 7.5mm film-coated tablets
Study: 35188874
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation for 8 weeks along with conventional dry eye treatment (artificial tears)
Study: 35188874
Drug: Conventional dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dry eye treatment (artificial tears) without vitamin D supplementation
Study: 35546255
Drug: Intradermal hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal hepatitis B vaccine with topical imiquimod pre‐treatment (ID-Imq)
Study: 35546255
Drug: Intramuscular hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hepatitis B vaccine with aqueous cream pre‐treatment (IM-Aq)
Study: 32246138
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefotaxime (250 mg/kg/day) with oral acetaminophen (first dose 30 mg/kg, then 20 mg/kg every 6 hours)
Study: 32246138
Drug: Cefotaxime conventionally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime conventionally as boluses (62.5 mg/kg, 4 times per day) with placebo orally
Study: 32246138
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefotaxime with oral acetaminophen
Study: 33105394
Drug: DriSti intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DriSti intervention (2 sessions with videos and interactive exercises on a computer tablet and one interactive face-to-face group session)
Study: 33106168
Drug: Placebo (288
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (288 mg of rice protein, 109.3 mg microcrystalline cellulose)
Study: 35246395
Drug: Tianjiang Xueshuantong
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tianjiang Xueshuantong Wan pills
Study: 35246395
Drug: rt‐PA intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA intravenous thrombolysis
Study: 616861719
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg immunologically active gluten/d
Study: 32191586
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg per day)
Study: 33950234
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment for 1 year (n=19)
Study: 33950234
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 1 year (n=18)
Study: 35236649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (benazepril hydrochloride tablets)
Study: 33849341
Drug: Vascular-targeted photodynamic
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular-targeted photodynamic therapy (PDT)
Study: 33849341
Drug: Salvage radical
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage radical prostatectomy (sRP) after focal therapy (FT)
Study: 33849341
Drug: Salvage radical
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage radical prostatectomy (sRP) after radiation therapy (RT)
Study: 34229502
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment group (Group 2)
Study: 33084773
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy during the infusion of 5-FU
Study: 33021877
Drug: Social and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social and Behaviour Change Communication intervention (weekly radio programming, listening and discussion groups, community engagement)
Study: 33098800
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (systolic blood pressure goal of less than 140 mm Hg)
Study: 34638151
Drug: Therapeutic-dose bemiparin
Normalized name: bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic-dose bemiparin (115 IU/kg daily)
Study: 34638151
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic dose (bemiparin 3,500 IU daily)
Study: 34638151
Drug: Therapeutic-dose bemiparin
Normalized name: bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic-dose bemiparin
Study: 34638151
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic dose
Study: 32738875
Drug: Topical citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical citicoline and vitamin B12 (Cit‐B12) 3 times daily for 18 months
Study: 32738875
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 times daily for 18 months
Study: 34898320
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (16 mg IV daily for 5 days followed by 8 mg daily for 5 days)
Study: 34898320
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (6 mg IV daily for 10 days)
Study: 36375083
Drug: Transurethral irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral irrigation with 0.01% lidocaine (100 mg in 1 L normal saline)
Study: 35841410
Drug: PBO +
Normalized name: INV-CIRB#20-18 (PREVENTABLE) ATORVASTATIN 40MG/PBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO + ERL (placebo with erlotinib 150 mg/day)
Study: 34184772
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg litoxetine
Study: 34184772
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg litoxetine
Study: 34184772
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg litoxetine
Study: 34184772
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg litoxetine
Study: 32825977
Drug: Fateh technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fateh technique (16-min soft tissue manipulation for four weekly sessions)
Study: 32825977
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise (two daily exercises for four weeks)
Study: 33690238
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with tamsulosin, dutasteride, and imidafenacin (TDI)
Study: 32087818
Drug: Nerinetide (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerinetide (2.6 mg/kg, max 270 mg)
Study: 32493475
Drug: Melatonin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2 mg orally before bedtime for 12 weeks)
Study: 34699040
Drug: Routine Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Standard Treatment with Vitamin C
Study: 34699040
Drug: Routine Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Standard Treatment with Alpha Lipoic Acid (ALA)
Study: 34699040
Drug: Routine Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Standard Treatment with Vitamin C and Alpha Lipoic Acid (ALA)
Study: 34699040
Drug: Routine Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Standard Treatment (RST)
Study: 32970395
Drug: EDS‐FLU 372
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS‐FLU 372 μg
Study: 32970395
Drug: EDS‐FLU 186
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS‐FLU 186 μg
Study: 32970395
Drug: Standard nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nasal steroid sprays
Study: 34411297
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment network analysis
Study: 32571560
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOA)
Study: 32068510
Drug: alfaxalone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfaxalone (5 mg/kg) and midazolam (0.5 mg/kg)
Study: 32068510
Drug: dexmedetomidine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine (0.05 mg/kg) and midazolam (0.5 mg/kg)
Study: 32068510
Drug: flumazenil (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: flumazenil (0.05 mg/kg) alone or in combination with atipamezole (0.5 mg/kg)
Study: 35247264
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine (n = 1008)
Study: 34651239
Drug: Subcutaneous wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous wound irrigation with 0.04% polyhexanide
Study: 34651239
Drug: Subcutaneous wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous wound irrigation with 0.9% saline
Study: 34914889
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg intravenously every 2 weeks)
Study: 36066977
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg subcutaneously) once weekly for 26 weeks
Study: 36066977
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg subcutaneously) once weekly for 26 weeks in a subgroup of obese patients
Study: 33009192
Drug: TCI‐PCA with
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCI‐PCA with target plasma concentrations between 0.8 and 10 ng/ml
Study: 33009192
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with bolus doses of 0.2 mg
Study: 36096886
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) treatment during the postoperative period
Study: 34120336
Drug: Gabapentin (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (3600 mg/day)
Study: 34427047
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for clinical high risk youth (FFT-CHR) - 18 1-hour sessions of family psychoeducation and communication/problem-solving skills training
Study: 36066501
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTA) injections, 50 units into both hands
Study: 36066501
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections into both hands
Study: 33839787
Drug: Amlodipine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (maximum 20 mg)
Study: 33839787
Drug: Prazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin GITS (maximum 30 mg)
Study: 32138661
Drug: 25 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/L GO
Study: 32138661
Drug: IAA (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAA (> 0.5 mg/L)